High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …

Simple Summary Bendamustine is a chemotherapeutic agent used to treat a variety of
cancers. It has recently been used in the context of allogeneic hematopoietic cell …

The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) as
conditioning regimen prior to autologous stem-cell transplantation (ASCT) remains the …

With the advent of new cellular and targeted therapies, treatment options for relapsed and
refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best …

Cytarabine-based immuno-chemotherapy followed by autologous stem cell transplantation
(ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL) …

High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT)
is the standard of care for patients with relapsed non-Hodgkin lymphoma (NHL), improving …

High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT)
remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM …

Autologous stem cell transplantation (ASCT) is an important treatment for peripheral T-cell
lymphoma (PTCL) patients both during front and salvage therapy. In order to explore the …

(1) Introduction: BEAM is a high-dose chemotherapy (HDCT) frequently administered before
autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL) …

In patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (HL), high-dose
chemotherapy (standard regimens include CBV, BEAC, and BEAM) with subsequent …